Last reviewed · How we verify

Felodipine add Metoprolol — Competitive Intelligence Brief

Felodipine add Metoprolol (Felodipine add Metoprolol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker + Beta-blocker combination. Area: Cardiovascular.

marketed Calcium channel blocker + Beta-blocker combination L-type calcium channels (felodipine); Beta-1 adrenergic receptor (metoprolol) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Felodipine add Metoprolol (Felodipine add Metoprolol) — LanZhou University. Felodipine and metoprolol together reduce blood pressure by relaxing blood vessels (felodipine) and slowing heart rate (metoprolol).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Felodipine add Metoprolol TARGET Felodipine add Metoprolol LanZhou University marketed Calcium channel blocker + Beta-blocker combination L-type calcium channels (felodipine); Beta-1 adrenergic receptor (metoprolol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker + Beta-blocker combination class)

  1. LanZhou University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Felodipine add Metoprolol — Competitive Intelligence Brief. https://druglandscape.com/ci/felodipine-add-metoprolol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: